美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

AgomAb Therapeutics

8.81

-0.2800-3.08%

成交量：3.74万

成交额：33.62万

市值：4.34亿

市盈率：-1.95

高：9.35

开：9.05

低：8.80

收：9.09

52周最高：17.82

52周最低：7.97

股本：4,924.80万

流通股本：1,383.60万

量比：0.59

换手率：0.27%

股息：- -

股息率：- -

每股收益(TTM):-4.5143

每股收益(LYR):-168.1598

净资产收益率：-39.22%

总资产收益率：-20.58%

市净率：4.19

市盈率(LYR):-0.05

数据加载中...

总览公司新闻资讯公告

概念

no data

没有相关数据

资金流向

资金流入：

资金流出：

新闻资讯

AgomAb Therapeutics影像学评估显示纤维化狭窄在治疗期间呈稳定趋势

Agomab Therapeutics：Ontunisertib治疗FSCD满60周，安全性与耐受性持续良好

Agomab Therapeutics：AGMB-447在IPF患者中展示出4.5毫克Bid剂量下的优越安全性与耐受性

Agomab公布Agmb-447特发性肺纤维化1期积极结果及2期Inspiria研究设计

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/hans/stock/AGMB"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"AGMB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AGMB\",,,,,undefined,":{"symbol":"AGMB","market":"US","secType":"STK","nameCN":"AgomAb Therapeutics","latestPrice":8.81,"timestamp":1791910286092,"preClose":9.09,"halted":0,"volume":37391,"delay":0,"changeRate":-0.030803080308030733,"floatShares":13836000,"shares":49248000,"eps":-4.51426,"marketStatus":"交易中","change":-0.28,"latestTime":"10-13 12:54:51 EDT","open":9.05,"high":9.35,"low":8.7976,"amount":336155.409916,"amplitude":0.06077,"askPrice":8.88,"askSize":100,"bidPrice":8.8,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-4.51426,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1791921600000},"marketStatusCode":2,"adr":0,"adrRate":1,"listingDate":1770354000000,"exchange":"NASDAQ","adjPreClose":9.09,"postHourTrading":{"tag":"盘后","latestPrice":9.09,"preClose":9.09,"latestTime":"19:30 EDT","volume":3315,"amount":30095.06,"timestamp":1791847802434,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.594133},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AGMB\",,,,,undefined,":{"symbol":"AGMB","floatShares":13836000,"roa":"-20.58%","roe":"-39.22%","lyrEps":-168.159829,"volumeRatio":0.594133,"shares":49248000,"dividePrice":0,"high":9.35,"amplitude":0.06077,"preClose":9.09,"low":8.7976,"week52Low":7.97,"pbRate":"4.19","week52High":17.82,"institutionHeld":0,"latestPrice":8.81,"eps":-4.51426,"divideRate":0,"volume":37391,"delay":0,"ttmEps":-4.51426,"open":9.05,"prevYearClose":16,"prevWeekClose":9.08,"prevMonthClose":11.1,"prevQuarterClose":11.1,"fiveDayClose":8.84,"twentyDayClose":12.16,"sixtyDayClose":11.98},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/AGMB\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"AGMB\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"AGMB\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.25,"buy":0.75,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.75,"analysts":8,"updateTime":1787889600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/AGMB\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"AGMB","date":"2026-10-12","current":-1.951593,"percent":0.970414,"low":-14.725744,"twenty":-10.889854,"median":-8.723279,"eighty":-7.452926,"high":-5.642551,"avg":-9.272426,"sd":2.263611,"marketCap":447171613},"quantilePoints":[{"date":"2026-02-06","current":-14.293959,"twenty":-14.293959,"median":-14.293959,"eighty":-14.293959,"marketCap":779788464},{"date":"2026-02-13","current":-13.901135,"twenty":-14.202947,"median":-13.85921,"eighty":-13.805127,"marketCap":763217959},{"date":"2026-02-20","current":-13.975141,"twenty":-14.020702,"median":-13.811207,"eighty":-13.436782,"marketCap":760781120},{"date":"2026-02-27","current":-14.297833,"twenty":-14.274685,"median":-13.837477,"eighty":-13.631029,"marketCap":780275831},{"date":"2026-03-06","current":-12.944797,"twenty":-14.315694,"median":-13.869306,"eighty":-13.479283,"marketCap":692549629},{"date":"2026-03-13","current":-12.71107,"twenty":-14.294734,"median":-13.805127,"eighty":-12.961754,"marketCap":677928595},{"date":"2026-03-20","current":-11.600011,"twenty":-14.274685,"median":-13.584093,"eighty":-12.695924,"marketCap":618957093},{"date":"2026-03-27","current":-10.84065,"twenty":-14.216331,"median":-13.160447,"eighty":-12.395453,"marketCap":578505566},{"date":"2026-04-02","current":-10.748527,"twenty":-14.066263,"median":-13.052487,"eighty":-11.414439,"marketCap":574119256},{"date":"2026-04-10","current":-9.193391,"twenty":-13.930737,"median":-12.827934,"eighty":-10.709469,"marketCap":497602513},{"date":"2026-04-17","current":-10.018749,"twenty":-13.86294,"median":-12.650405,"eighty":-9.901184,"marketCap":545851924},{"date":"2026-04-24","current":-9.622204,"twenty":-13.825362,"median":-12.457995,"eighty":-9.650988,"marketCap":521483535},{"date":"2026-05-01","current":-7.206485,"twenty":-13.809991,"median":-11.744798,"eighty":-9.486381,"marketCap":528794052},{"date":"2026-05-08","current":-7.639457,"twenty":-13.779732,"median":-11.111376,"eighty":-9.258769,"marketCap":562411874},{"date":"2026-05-15","current":-7.446972,"twenty":-13.702513,"median":-10.748527,"eighty":-8.300034,"marketCap":543697644},{"date":"2026-05-22","current":-7.434647,"twenty":-13.568448,"median":-10.364346,"eighty":-8.115636,"marketCap":538772846},{"date":"2026-05-29","current":-7.796965,"twenty":-13.4527,"median":-9.998785,"eighty":-7.794875,"marketCap":568321631},{"date":"2026-06-05","current":-8.053102,"twenty":-13.287949,"median":-9.784729,"eighty":-7.758816,"marketCap":585558422},{"date":"2026-06-12","current":-6.750851,"twenty":-13.127527,"median":-9.578953,"eighty":-7.536224,"marketCap":486569993},{"date":"2026-06-18","current":-6.929006,"twenty":-13.073014,"median":-9.501773,"eighty":-7.448225,"marketCap":497404547},{"date":"2026-06-26","current":-9.2886,"twenty":-13.035188,"median":-9.467948,"eighty":-7.458553,"marketCap":661400304},{"date":"2026-07-02","current":-8.166663,"twenty":-12.965993,"median":-9.467948,"eighty":-7.479819,"marketCap":584573463},{"date":"2026-07-10","current":-8.975013,"twenty":-12.944797,"median":-9.309036,"eighty":-7.532768,"marketCap":641701114},{"date":"2026-07-17","current":-8.479177,"twenty":-12.71107,"median":-9.193391,"eighty":-7.541408,"marketCap":606735052},{"date":"2026-07-24","current":-8.981683,"twenty":-12.707304,"median":-9.020605,"eighty":-7.554336,"marketCap":638746235},{"date":"2026-07-31","current":-8.723327,"twenty":-12.661785,"median":-8.978348,"eighty":-7.610114,"marketCap":628157921},{"date":"2026-08-07","current":-9.22434,"twenty":-12.557349,"median":-9.00807,"eighty":-7.636377,"marketCap":664847662},{"date":"2026-08-14","current":-8.931525,"twenty":-12.519309,"median":-9.035172,"eighty":-7.716456,"marketCap":686763011},{"date":"2026-08-21","current":-8.496488,"twenty":-12.423423,"median":-8.981683,"eighty":-7.781927,"marketCap":661400304},{"date":"2026-08-28","current":-8.778373,"twenty":-12.380686,"median":-8.974146,"eighty":-7.796268,"marketCap":681591974},{"date":"2026-09-04","current":-9.428222,"twenty":-12.300242,"median":-8.931525,"eighty":-7.867232,"marketCap":730347469},{"date":"2026-09-11","current":-8.858281,"twenty":-11.959423,"median":-8.973278,"eighty":-7.956453,"marketCap":686516771},{"date":"2026-09-18","current":-7.774516,"twenty":-11.657926,"median":-8.880371,"eighty":-7.795572,"marketCap":594915538},{"date":"2026-09-25","current":-6.876368,"twenty":-11.321652,"median":-8.807045,"eighty":-7.758992,"marketCap":521043575},{"date":"2026-10-02","current":-5.676951,"twenty":-11.106435,"median":-8.772569,"eighty":-7.554749,"marketCap":425994983},{"date":"2026-10-09","current":-6.083739,"twenty":-10.939059,"median":-8.723327,"eighty":-7.469186,"marketCap":454066329},{"date":"2026-10-12","current":-6.006122,"twenty":-10.889854,"median":-8.723279,"eighty":-7.452926,"marketCap":447171613}],"updateTime":1791910491413},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"AGMB\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1117111798","title":"AgomAb Therapeutics影像学评估显示纤维化狭窄在治疗期间呈稳定趋势","url":"https://stock-news.laohu8.com/highlight/detail?id=1117111798","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1117111798?lang=zh_cn&edition=fundamental","pubTime":"2026-10-01 18:31","pubTimestamp":1790850718,"startTime":"0","endTime":"0","summary":"AgomAb Therapeutics影像学评估显示纤维化狭窄在治疗期间呈稳定趋势","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AGMB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112672519","title":"Agomab Therapeutics：Ontunisertib治疗FSCD满60周，安全性与耐受性持续良好","url":"https://stock-news.laohu8.com/highlight/detail?id=1112672519","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1112672519?lang=zh_cn&edition=fundamental","pubTime":"2026-10-01 18:31","pubTimestamp":1790850669,"startTime":"0","endTime":"0","summary":"Agomab Therapeutics Nv 宣布，其药物 Ontunisertib 在治疗纤维性狭窄性克罗恩病（FSCD）的过程中，长达 60 周的疗程里始终维持了令人满意的安全性与耐受性表现。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AGMB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108737836","title":"Agomab Therapeutics：AGMB-447在IPF患者中展示出4.5毫克Bid剂量下的优越安全性与耐受性","url":"https://stock-news.laohu8.com/highlight/detail?id=1108737836","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1108737836?lang=zh_cn&edition=fundamental","pubTime":"2026-09-15 04:13","pubTimestamp":1789416788,"startTime":"0","endTime":"0","summary":"Agomab Therapeutics公司今日宣布，其候选药物AGMB-447在特发性肺纤维化（IPF）患者中展现出令人鼓舞的安全性和耐受性数据。该项研究聚焦于4.5毫克每日两次（Bid）的给药方案，初步结果令人振奋。\n数据表明，该剂量水平下的药物耐受性表现良好，患者未出现预期之外的不良事件。这一发现为AGMB-447的后续临床开发奠定了坚实基础。\n作为一家专注于纤维化疾病治疗领域的生物制药企业，Agomab Therapeutics正积极推进该候选药物的临床研究进程。此次公布的结果进一步验证了公司在纤维化治疗管线上的战略布局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AGMB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108518383","title":"Agomab公布Agmb-447特发性肺纤维化1期积极结果及2期Inspiria研究设计","url":"https://stock-news.laohu8.com/highlight/detail?id=1108518383","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1108518383?lang=zh_cn&edition=fundamental","pubTime":"2026-09-15 04:06","pubTimestamp":1789416373,"startTime":"0","endTime":"0","summary":"Agomab近日对外宣布，其针对特发性肺纤维化患者所研发的在研药物Agmb-447，在1期临床试验中取得了令人振奋的积极数据。与此同时，该公司还正式揭晓了即将启动的2期临床研究——Inspiria研究的设计方案。关于2期Inspiria研究的规划，Agomab表示将基于1期所确立的给药方案与剂量范围，进一步深入评估Agmb-447在更大规模患者群体中的疗效与安全性。随着2期研究的即将铺开，业内目光已聚焦于Agomab能否延续其研发势能，以及Inspiria研究最终能收获怎样的临床答卷。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AGMB"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":2,"pageCount":1,"totalSize":6,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/AGMB\",params:#limit:6,delay:false,,,undefined,":[]}}